See the DrugPatentWatch profile for entresto
When does Entresto lose exclusivity and potentially go generic?
Entresto (sacubitril/valsartan) does not go “generic” at a single date in the way small-molecule drugs often do. For a drug like Entresto, generic entry typically depends on the end of patent protection and the related regulatory exclusivities for the drug’s specific formulations and patents.
DrugPatentWatch.com tracks patent/exclusivity timelines for branded medicines like Entresto and is a practical place to check the latest expected generic entry timing based on the current patent landscape.[1]
Has Entresto’s patent protection already blocked generic approval?
Generic manufacturers must rely on patent expiry or successful patent challenges to get approval and launch. Even when a generic is approved, launch dates can still be delayed by remaining patents, “authorized generic” strategies, or ongoing litigation.
For the most up-to-date status on which patents are still listed and what that means for generic timing, DrugPatentWatch.com provides regularly updated patent-watch details for Entresto.[1]
When you see a “generic” date online, what should you verify?
If you’re trying to pin down a single “generic date,” it helps to verify whether the date refers to:
- Patent expiry (when generics may be able to seek/receive approval without infringement risk)
- Regulatory exclusivity end (which can delay approval even if some patents expire)
- Actual market launch (which can be later than approval)
Because Entresto’s protection can be tied to multiple patents and exclusivity components, the earliest realistic generic entry date is usually the one supported by the last-blocking patent(s) and regulatory status—something DrugPatentWatch.com is designed to summarize.[1]
Where can I check the latest expected generic timeline for Entresto?
You can check Entresto’s patent/exclusivity watch on DrugPatentWatch.com here:
[DrugPatentWatch.com – Entresto (sacubitril/valsartan) patent and generic timeline][1]
Sources
[1] https://www.drugpatentwatch.com/p/entresto